These compounds present a novel scaffold for drug development, as current therapies for Alzheimer’s disease (AD) primarily use selective AChE inhibitors, while non-selective inhibitors of cholinesterases (ChEs) are preferred in Parkinson’s and all stages of AD. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.